| Document |
Document Title |
|
WO/2023/191597A1 |
The present invention relates to: natural killer cells produced and mass-proliferated from induced pluripotent stem cells; and a pharmaceutical composition comprising same as an active ingredient. The natural killer cells according to th...
|
|
WO/2023/190675A1 |
[Problem] To provide a novel compound having TrkB-binding activity. [Solution] A peptide complex having TrkB-binding activity comprises a first peptide having an amino acid sequence represented by X1-X2-X3-X4-3Py-W-X5-X6-X7-X8-X9-X10-V-X...
|
|
WO/2023/191468A1 |
The present invention relates to nitrogen-containing heterocyclic compound derivatives and uses thereof. The compounds according to the present invention can exert therapeutic effects on various neurological disorders, such as neurodegen...
|
|
WO/2023/184473A1 |
The present invention relates to a use of a peptide in treating neurodegenerative diseases or improving cognitive function. The present invention relates to the treatment of neurodegenerative diseases and cognitive disorders, and the imp...
|
|
WO/2023/187790A1 |
A method of treating an inflammatory disease or disorder of the central nervous system (CNS) in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent cap...
|
|
WO/2023/190465A1 |
Provided is a functional human anti-SEMA7A antibody. This invention relates to an anti-SEMA7A antibody in human having a specific CDR sequence, or an antibody fragment of this antibody.
|
|
WO/2023/187182A1 |
The present disclosure relates to a compound of formula (I) wherein R1 represents a hydrogen atom, a -(C1-C6)alkyl group optionally substituted; R2 represents a hydrogen atom, a halogen atom, a -(C1-C6)alkyl group, a -(C3-C7)cycloalkyl g...
|
|
WO/2023/184688A1 |
Provided are a functional β-galactosidase, such as a functional variant of human β-galactosidase, and pharmaceutical use thereof. Also provided are an optimized human β-galactosidase gene expression cassette, a recombinant adeno-assoc...
|
|
WO/2023/186062A1 |
The present invention relates to use of a peptide in treating a neurodegenerative disease or ameliorating a cognitive function. The present invention relates to the treatment of neurodegenerative diseases and cognitive disorders, and the...
|
|
WO/2023/186829A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from social/emotional withdrawal or detachment.
|
|
WO/2023/187838A1 |
Phialomustin B (1) for treatment of Parkinson's disease (PD) and Amyotrophic lateral sclerosis (ALS) The present invention provides Phialomustin B (1) a natural product isolated from the endophytic fungus Phialophora Mustea from the Corm...
|
|
WO/2023/187421A1 |
The application relates to the besylate, phosphate, tartrate, fumarate and succinate salts of mesembrine, also known as 3a-(3,4- dimethoxyphenyl)-octahydro-1-methyl-6H-indol-6-one. Mesembrine has the chemical formula C17H23NO3. The appli...
|
|
WO/2023/186821A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from negative thinking, wherein the 5-MeO- DMT or a pharmaceutically acceptable salt thereof is administer...
|
|
WO/2023/186826A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD).
|
|
WO/2023/185861A1 |
Provided are a guide nucleic acid targeting human UBE3A-ATS, system or composition or rAAV vector genome comprising the same,and a method using the same for treating human UBE3A-ATS associated disease and disorders.
|
|
WO/2023/191648A1 |
This invention relates to prodrugs of opicapone, their synthetic intermediates and pharmaceutically acceptable salts thereof. The invention also relates to methods of preparation of prodrugs of opicapone and pharmaceutically acceptable s...
|
|
WO/2023/187091A1 |
The present invention relates to a sphingosine-1-phosphate receptor (S1PR) modulator for use in treating a patient suffering from Alzheimer's dementia.
|
|
WO/2023/184470A1 |
The present invention relates to the therapeutic use of extracts from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extracts from rabbit skin inflamed by vaccinia virus in the trea...
|
|
WO/2023/186798A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from sleep disturbance, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administere...
|
|
WO/2023/186831A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from psychomotor retardation, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is admin...
|
|
WO/2023/186824A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from cognitive dysfunction, wherein the 5- MeO-DMT or a pharmaceutically acceptable salt thereof is admini...
|
|
WO/2023/192290A1 |
Disclosed are methods for treating a subject having multiple system atrophy (MSA) using ampreloxetine or a pharmaceutically acceptable salt thereof. The methods disclosed include using ampreloxetine or a pharmaceutically acceptable salt ...
|
|
WO/2023/186820A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from negative thinking.
|
|
WO/2023/187789A1 |
A method of treating a brain tumor in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating activity or expression of a compone...
|
|
WO/2023/192362A1 |
Methods of treating a subject for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are provided. Aspects of the methods include administering to the subject a tropane CCR5/CCL5 interaction inhibitor, either alone or in combina...
|
|
WO/2023/186828A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from anxiety, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the ...
|
|
WO/2023/192288A1 |
In one aspect, monovalent binding molecules that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided, as well as methods of use thereof.
|
|
WO/2023/187099A1 |
The invention relates to morphinan-derivatives, processes for their preparation, medicaments containing them and the use of these morphinan-derivatives for the preparation of medicaments.
|
|
WO/2023/187223A1 |
There is provided a powder comprising a solid, porous chemically bonded ceramic system and nicotine or a salt thereof, wherein the nicotine or salt thereof is located within pores of the chemically bonded ceramic system. An intraoral for...
|
|
WO/2023/186832A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from social/emotional withdrawal or detachment, wherein the 5-MeO-DMT or a pharmaceutically acceptable sal...
|
|
WO/2023/186797A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from sleep disturbance.
|
|
WO/2023/190826A1 |
The present invention relates to a pharmaceutical composition for preventing, suppressing, or treating the symptoms that accompany pseudo-allergic reactions, said pharmaceutical composition comprising, as an active ingredient, a compound...
|
|
WO/2023/186837A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a p...
|
|
WO/2023/187783A1 |
Newly designed compounds represented by Formulae I-V as described in the instant specification and uses thereof as pancreatic endoplasmic reticulum kinase (PERK) activators and in treating associated medical conditions, including viral i...
|
|
WO/2023/191951A1 |
The present invention relates to novel 5HT receptor modulators, such as compounds of the general Formula (I) and general Formula (II): or a pharmaceutically acceptable salt thereof. Methods of using the compounds include, for example, mo...
|
|
WO/2023/191997A1 |
Compositions and methods are provided that mitigate iron imbalance resulting from inflammation and/or mitigate the effects of inflammatory disease. This can be accomplished by correcting dysregulation of iron internalization. Such correc...
|
|
WO/2023/187067A1 |
Disclosed herein is a method of co-formulating an amylin receptor agonist and a GLP-1 receptor agonist. Disclosed herein is a liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist and a cyclode...
|
|
WO/2023/186963A1 |
Combination drug therapies comprising a 5-HT2A receptor agonist and an N-methyl-D- aspartate (NMDA) receptor antagonist (e.g., nitrous oxide, xenon, argon, ketamine, etc.) are provided. Also described are pharmaceutical compositions and ...
|
|
WO/2023/186827A1 |
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular ...
|
|
WO/2023/185878A1 |
Provided are engineered Cas13f polypeptides, system or compositions comprising the same, and methods of using the same.
|
|
WO/2023/184986A1 |
The present invention provides use of a CD36 inhibitor in preparing a medicament for inhibiting scarring after spinal cord injury. The present invention relates to the field of biotechnology, and particularly to use of a CD36 inhibitor i...
|
|
WO/2023/185017A1 |
Provided is modified RNF112 or an exosome delivery system containing same. Further provided is a fusion RNA or a fusion DNA, wherein the fusion RNA or the fusion DNA contains a coding sequence of the modified RNF112 protein, which coding...
|
|
WO/2023/192984A1 |
Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate GSK3|3 signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin...
|
|
WO/2023/190809A1 |
The present invention addresses the problem of providing: a new food component that inhibits production of cortisol; and a composition containing the food component. The present invention provides a composition that is for inhibiting p...
|
|
WO/2023/190496A1 |
The present invention provides: an anti-netrin-4 antibody capable of recognizing, as an epitope, an amino acid sequence (SEQ ID NO: 2) lying between position-192 to position-202 in an amino acid sequence (SEQ ID NO: 1) for human netrin-4...
|
|
WO/2023/187224A1 |
There is provided an intraoral formulation comprising a solid, porous chemically bonded ceramic system, nicotine or a salt thereof, and a pH regulating agent, wherein the chemically bonded ceramic system is formed in the absence of said ...
|
|
WO/2023/192453A1 |
A method of treating a patient having a cerebral artery dysfunction is provided comprising administering to a patient a pharmaceutically effective amount of a xanthine oxidase inhibitor to said patient for treating a cerebral artery dysf...
|
|
WO/2023/190797A1 |
Provided are technique for improving muscle quality and technique related thereto. The present invention improves muscle quality by using a choline compound such as sn-Glycero-3-phosphocholine (αGPC) or citicoline.
|
|
WO/2023/186059A1 |
Disclosed is a method for culturing a genetically engineered cell for treating Parkinson's disease. By introducing the three key genes required for the synthesis of neurotransmitter dopamine (DA), namely tyrosine hydroxylase (TH), aromat...
|
|
WO/2023/185979A1 |
Provided are a preparation method for and use of crystalline forms of an ATX inhibitor represented by formula (I) and a salt thereof. The crystalline forms of the ATX inhibitor and the salt thereof have high oral bioavailability, low hyg...
|
